Member Info for boak

News says this morning that the USA has bought up nearly the whole worlds supply of Remdesivir.

Remdesivir, an antiviral originally designed to fight ebola, is the only drug shown to have any effect in combating Covid-19. It will soon be available to some of those in greatest need, Matt Han****, the health secretary, announced yesterday.

https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=newssearch&cd=&cad=rja&uact=8&ved=2ahUKEwjPmrOJstPpAhX-RBUIHePBCJ4Q-MoFegQIABAJ&url=https%3A%2F%2Fwww.thetimes.co.uk%2Farticle%2Fnhs-drug-remdesivir-promises-big-step-forward-in-coronavirus-treatment-j30nbf5q2&usg=AOvVaw2w-uhtUvuM-JHthJRhhNN0

Shared from Sky News: Coronavirus: NHS to treat severe COVID-19 patients with Ebola drug to speed up recovery https://news.sky.com/story/coronavirus-nhs-to-treat-severe-covid-19-patients-with-ebola-drug-to-speed-up-recovery-11994848

https://live.euronext.com/en/product/equities/FR0010397232-ALXP

BBC mentioned Gilead Sciences on lunchtime news. Also worth checking Remdesivir name of drug as it is in the FT, Bloomberg and Reuters. Seems positive news on it. I also hold Novacyt.

Not only there also mentioned in the FT, Bloomberg and Reuters. Google them, it mentions Remdesivir. Looking positive hope so for all patients.

https://live.euronext.com/en/product/equities/FR0010397232-ALXP

Boris Johnson may try Remdesivir from Gilead Sciences

This drug mentioned on TV this morning and made by Gilead Sciences may help Boris Hohnson who is in intensive care with Coronavirus.

I hold NCYT and reading about Gilead Science last week who have a drug called Remdesivir it said on TV this morning it may help Boris Johnson who now has Coronavirus.

Holding both of these for much the same reasons. GILD is in the US, I have it in my Quick Picks on LSE as I do with NCYT based in Paris and Camberley.

Hold both NCYT and GILD in the US for much the same reasons.

Got a few in my ISA last week with so much happenng on the US. Bought withHL.

Gilead Sciences

Got some in my ISA with HL. TKS.

Novacyt Primerdesign Coronavirus Dx Test Receives FDA Emergency Use Authorization
Mar 23, 2020 | staff reporter
NEW YORK – The US Food and Drug Administration on Friday granted Emergency Use Authorization for a molecular diagnostic test for SARS-CoV-2 developed by Primerdesign, the UK-based molecular diagnostics division of clinical diagnostics company Novacyt.

The Primerdesign COVID-19 Genesig Real-Time PCR assay, which received CE marking in mid-February, is a real-time RT-PCR test for the qualitative detection of SARS-CoV-2 nucleic acid in oropharyngeal swabs from patients suspected to have COVID-19. It is immediately available for distribution in the US.

The test kits include Primerdesign's master mix, relevant primers and probes, positive controls, and internal RNA extraction controls. The test is used with the GXT DNA/RNA Extraction kit and GenoXtract extraction instrument from Bruker-Hain Lifescience, and can be run on Thermo Fisher Scientific's Applied Biosystems 7500 Real-Time PCR System, Bio-Rad Technologies' CFX Connect Real-Time PCR Detection System, or Roche's LightCycler 480 II platform, according the manufacturer's insert.

https://novacyt.com/news-and-events/

07/02/20
Posted in Board, Novacyt Group, NOVAPREP®, Products, Services, Uncategorized
Update on novel coronavirus test

Paris, France and Camberley, UK – 7 February 2020 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, provides an update following the launch of its research use only (RUO) test for novel coronavirus (2019-nCoV), which has been developed by its subsidiary Primerdesign as a direct response to the recent outbreak

https://www.google.com/search?client=safari&rls=en&q=novacyt&ie=UTF-8&oe=UTF-8